Navigation Links
Generic Pharma Partnering Yearbook 2013 - Access to the Partnering Deals and Agreements Globally
Date:1/31/2013

omprehensive directory of all partnering deals announced during 2012. 
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.

Key benefits

Generic Pharma Partnering Yearbook 2013 series provides the reader with the following key benefits:

  • In-depth understanding of recent dealmaking trends during 2012
  • Comprehensive access to all deals entered into by the world's biopharma companies during 2012
  • Detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Generic Pharma Partnering Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.

Generic Pharma Partnering Yearbook 2013 includes:

  • Trends in dealmaking in the biopharma industry during 2012
  • Comprehensive directory of
    '/>"/>

SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Watsons Generic Yaz(R) Receives FDA Approval
2. Watsons Generic BONIVA® 150mg Receives FDA Approval
3. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. Lupin Receives FDA Approval for Generic LYRICA(R)
6. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
(Date:9/18/2014)... September 18, 2014 Pipette.com announces ... Sartorius/Biohit, Socorex, Capp, and AccuPet brand of pipettes. ... 100 uL or less and are a great ... applications. , The micropipette promotions were designed ... economic alternative products to help customers find the ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3
... on its recent analysis of new products within the ... the 2012 North American Frost & Sullivan Award for ... a "gold standard" polymerase chain reaction (PCR) instrument. The ... amplification, and detection, all in a multiplexed, automated, and ...
... Inc. (NYSE Amex: BONE ), a leader in ... for medical applications, today announced its financial results for the ... Fourth Quarter 2011 Highlights: Revenue ... for the fourth quarter of 2010. Operating loss decreased ...
... March 21, 2012 When deciding between the ... the upcoming and existing research programs prove highly ... introduces the Life Sciences Content: Pharmaceuticals, Biotechnology, ... to 2012 compendium.  This resource includes Frost ...
Cached Biology Technology:Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 2Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 3Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 2Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 3
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... known as 'tandem running' to lead another ant from the ... control both the speed and course of the run. It ... 'formal' teaching has been recognised in any non-human animal. , ... information, rather than the constraint of brain size, that has ...
... Neil Ferguson, and Geoff Garnett (of Imperial College London) ... not be controlled through antiretroviral drugs alone, even if ... article in the open-access international medical journal PLoS Medicine, ... their communities about safe sex, access to drugs is ...
... Hopkins researchers have discovered a gene in fruit flies ... bright light. The study, published in the April 4 ... sensory perception in mammals. , In teasing apart the ... studied a gene they dubbed "Lazaro" that is expressed ...
Cached Biology News:First demonstration of 'teaching' in non-human animals 2Access to antiretrovirals unlikely to reduce HIV infection rates 2New gene reduces retinal degeneration in fruit flies 2
Request Info...
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
...
Biology Products: